FDA accepts application for Salix Pharmaceuticals’ new bowel cleansing preparation — 4 key notes

The FDA approved Salix Pharmaceutical’s new drug application for Plenvu, a lower-volume polyethylene glycol-based bowel preparation developed for bowel cleansing.

Advertisement

Here’s what you should know:

1. Plenvu additionally focuses on preparing the ascending colon.

2. If approved, Plenvu will tout the lowest total volume of solution for a bowel cleanser.

3. Salix expects an FDA decision in the first quarter of fiscal year 2018.

4. Salix is a subsidiary of Valeant Pharmaceuticals.

More articles on gastroenterology:
Synthetic Biologics receives Patent office allowance for active agent in IBS-C treatment — 3 key notes
GI center to know: Gastroenterology of the Rockies
Exact Sciences partners with pro-golfer & more — 6 GI company key notes

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.